Isolated CNS relapse in human epidermal growth factor receptor 2-positive esophagogastric cancer: effective treatment with trastuzumab after failure of surgery and radiotherapy

J Clin Oncol. 2011 Aug 10;29(23):e664-5. doi: 10.1200/JCO.2011.35.8317. Epub 2011 Jun 6.

Authors

Tom Geldart¹, George Astras

Affiliation

¹ Royal Bournemouth Hospital, Bournemouth, United Kingdom.

PMID: 21646609
DOI: 10.1200/JCO.2011.35.8317

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Adenocarcinoma / secondary
Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols
Brain Neoplasms / drug therapy
Brain Neoplasms / secondary
Brain Neoplasms / surgery
Combined Modality Therapy
Digestive System Surgical Procedures
Esophageal Neoplasms / drug therapy*
Esophageal Neoplasms / genetics
Esophageal Neoplasms / pathology
Esophagogastric Junction / pathology
Humans
Male
Receptor, ErbB-2 / genetics*
Salvage Therapy / methods
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / genetics
Stomach Neoplasms / secondary
Trastuzumab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
ERBB2 protein, human
Receptor, ErbB-2
Trastuzumab